Cheilitis Granulomatosa Medication
- Author: Crispian Scully, MD, PhD, MDS, CBE, MRCS, FDSRCS, FDSRCPS, FFDRCSI, FDSRCSE, FRCPath, FMedSci, FHEA, FUCL, DSc, DChD, DMed(HC), Dr(HC), ; Chief Editor: Dirk M Elston, MD more...
Medication Summary
None of the agents listed below has been systematically evaluated.
Immunomodulatory agents are as follows:
- Nonsteroidal anti-inflammatory agents (NSAIDs)
- Mast cell stabilizers[22]
- Clofazimine[23]
- Methotrexate[24]
- Tacrolimus
- Infliximab[25]
- Dapsone
- Triamcinolone and dapsone injections[26]
Antimicrobials are as follows:
- Tetracycline (used for anti-inflammatory activity)
- Minocycline[27]
- Roxithromycin[28]
- Antibiotic treatment of dental abscess - Resulted in remission in anecdotal cases
Intralesional corticosteroid (triamcinolone) injections may reduce swelling. Systemic corticosteroids are rarely indicated and not all cases respond.
No randomized, controlled trials have yet been recorded with possible therapies such as tacrolimus, thalidomide, or infliximab.
Antibiotics, Other
Class Summary
Therapy must be comprehensive and should cover all likely pathogens in the clinical setting.
Clofazimine (Lamprene)
Clofazimine inhibits mycobacterial growth, binding preferentially to mycobacterial deoxyribonucleic acid (DNA). It has antimicrobial properties, but the mechanism of action is unknown.
Dapsone
Dapsone is bactericidal and bacteriostatic against mycobacteria. Its mechanism of action is similar to that of sulfonamides in which competitive antagonists of para-aminobenzoic acid (PABA) prevent formation of folic acid, inhibiting bacterial growth.
Penicillin G (Pfizerpen)
Penicillin G interferes with the synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.
Doxycycline (Doryx, Adoxa, Ocudox, Vibramycin, Oraxyl)
Doxycycline is a broad-spectrum, synthetically derived bacteriostatic antibiotic in the tetracycline class. It is almost completely absorbed, concentrates in bile, and is excreted in urine and feces as a biologically active metabolite in high concentrations.
Doxycycline inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly the 50S ribosomal subunits of susceptible bacteria. It may block dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Erythromycin (E.E.S., Ery-Tab, Erythrocin, PCE, EryPed)
Erythromycin covers most potential etiologic agents, including Mycoplasma species. The oral regimen may be insufficient to adequately treat Legionella species, and this agent is less active against Haemophilus influenzae. Although the standard course of treatment is 10 days, treatment until the patient has been afebrile for 3-5 days seems a more rational approach. Erythromycin therapy may result in GI upset, causing some clinicians to prescribe an alternative macrolide or change to a thrice-daily dosing.
Erythromycin is a macrolide that inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Mast Cell Stabilizers
Class Summary
Mast cell stabilizers inhibit the degeneration of sensitized mast cells when exposed to specific antigens by inhibiting the release of mediators from the mast cells. These agents block calcium ions from entering the mast cell.
Ketotifen
Ketotifen is an H1-receptor antagonist and mast cell stabilizer. This agent inhibits the release of mediators from cells involved in hypersensitivity reactions.
Salicylates
Class Summary
These agents decrease inflammatory responses and systemically interfere with events leading to inflammation.
Sulfapyridine
Sulfapyridine is a competitive antagonist of PABA. Its mechanism of action in linear immunoglobulin-A (IgA) dermatosis is unknown. It is no longer available in the US market. It is available only as an orphan drug.
Sulfasalazine (Azulfidine)
Sulfasalazine decreases the inflammatory response and systemically inhibits prostaglandin synthesis.
Corticosteroids
Class Summary
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.
Triamcinolone (Aristospan, Kenalog)
Triamcinolone is used to treat inflammatory dermatosis that is responsive to steroids. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.
Immunosuppressants
Class Summary
These agents inhibit key factors that mediate immune reactions, which, in turn, decrease inflammatory responses.
Azathioprine (Imuran, Azasan)
Azathioprine antagonizes purine metabolism and inhibits the synthesis of DNA, ribonucleic acid (RNA), and proteins. It may decrease the proliferation of immune cells, which results in lower autoimmune activity.
Ficarra G, Cicchi P, Amorosi A, Piluso S. Oral Crohn's disease and pyostomatitis vegetans. An unusual association. Oral Surg Oral Med Oral Pathol. Feb 1993;75(2):220-4. [Medline].
Khouri JM, Bohane TD, Day AS. Is orofacial granulomatosis in children a feature of Crohn's disease?. Acta Paediatr. Apr 2005;94(4):501-4. [Medline].
Narbutt P, Dziki A. Re: Melkersson-Rosenthal syndrome as an early manifestation of Crohn's disease. Colorectal Dis. Jul 2005;7(4):420-1. [Medline].
Scully C, Cochran KM, Russell RI, Ferguson MM, Ghouri MA, Lee FD, et al. Crohn's disease of the mouth: an indicator of intestinal involvement. Gut. Mar 1982;23(3):198-201. [Medline].
Williams AJ, Wray D, Ferguson A. The clinical entity of orofacial Crohn's disease. Q J Med. May 1991;79(289):451-8. [Medline].
Blinder D, Yahatom R, Taicher S. Oral manifestations of sarcoidosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Apr 1997;83(4):458-61. [Medline].
McCartan BE, Healy CM, McCreary CE, Flint SR, Rogers S, Toner ME. Characteristics of patients with orofacial granulomatosis. Oral Dis. Oct 2011;17(7):696-704. [Medline].
Ketabchi S, Massi D, Ficarra G, et al. Expression of protease-activated receptor-1 and -2 in orofacial granulomatosis. Oral Dis. Jul 2007;13(4):419-25. [Medline].
Tilakaratne WM, Freysdottir J, Fortune F. Orofacial granulomatosis: review on aetiology and pathogenesis. J Oral Pathol Med. Apr 2008;37(4):191-5. [Medline].
Saalman R, Sundell S, Kullberg-Lindh C, Lövsund-Johannesson E, Jontell M. Long-standing oral mucosal lesions in solid organ-transplanted children-a novel clinical entity. Transplantation. 2010;89:606.
McKenna KE, Walsh MY, Burrows D. The Melkersson-Rosenthal syndrome and food additive hypersensitivity. Br J Dermatol. Dec 1994;131(6):921-2. [Medline].
Morales C, Penarrocha M, Bagan JV, Burches E, Pelaez A. Immunological study of Melkersson-Rosenthal syndrome. Lack of response to food additive challenge. Clin Exp Allergy. Mar 1995;25(3):260-4. [Medline].
Wong GA, Shear NH. Melkersson-Rosenthal syndrome associated with allergic contact dermatitis from octyl and dodecyl gallates. Contact Dermatitis. Nov 2003;49(5):266-7. [Medline].
White A, Nunes C, Escudier M, et al. Improvement in orofacial granulomatosis on a cinnamon- and benzoate-free diet. Inflamm Bowel Dis. Jun 2006;12(6):508-14. [Medline].
Khandpur S, Malhotra AK, Khanna N. Melkersson-Rosenthal syndrome with diffuse facial swelling and multiple cranial nerve palsies. J Dermatol. Jun 2006;33(6):411-4. [Medline].
Saito T, Hida C, Tsunoda I, Tsukamoto T, Yamamoto T. Melkersson-Rosenthal syndrome: distal facial nerve branch palsies, masseter myopathy and corticosteroid treatment. Fukushima J Med Sci. Jun 1994;40(1):39-44. [Medline].
Fitzpatrick L, Healy CM, McCartan BE, Flint SR, McCreary CE, Rogers S. Patch testing for food-associated allergies in orofacial granulomatosis. J Oral Pathol Med. Jan 2011;40(1):10-3. [Medline].
[Guideline] Grave B, McCullough M, Wiesenfeld D. Orofacial granulomatosis--a 20-year review. Oral Diseases. 2009;15:46-51.
Campbell HE, Escudier MP, Patel P, Challacombe SJ, Sanderson JD, Lomer MC. Review article: cinnamon- and benzoate-free diet as a primary treatment for orofacial granulomatosis. Aliment Pharmacol Ther. Oct 2011;34(7):687-701. [Medline].
Williams PM, Greenberg MS. Management of cheilitis granulomatosa. Oral Surg Oral Med Oral Pathol. Oct 1991;72(4):436-9. [Medline].
Kruse-Losler B, Presser D, Metze D, Joos U. Surgical treatment of persistent macrocheilia in patients with Melkersson-Rosenthal syndrome and cheilitis granulomatosa. Arch Dermatol. Sep 2005;141(9):1085-91. [Medline].
Kano Y, Shiohara T, Yagita A, Nagashima M. Treatment of recalcitrant cheilitis granulomatosa with metronidazole. J Am Acad Dermatol. Oct 1992;27(4):629-30. [Medline].
Fdez-Freire LR, Serrano Gotarredona A, Bernabeu Wittel J, Pulpillo Ruiz A, Cabrera R, Navarrete Ortega M, et al. Clofazimine as elective treatment for granulomatous cheilitis. J Drugs Dermatol. May-Jun 2005;4(3):374-7. [Medline].
Tonkovic-Capin V, Galbraith SS, Rogers RS 3rd, Binion DG, Yancey KB. Cutaneous Crohn's disease mimicking Melkersson-Rosenthal syndrome: treatment with methotrexate. J Eur Acad Dermatol Venereol. Apr 2006;20(4):449-52. [Medline].
Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol. Sep 2005;141(9):1080-2. [Medline].
Sobjanek M, Wlodarkiewicz A, Zelazny I, Nowicki R, Michajlowski I, Sokolowska-Wojdylo M. Successful treatment of Melkersson-Rosenthal syndrome with dapsone and triamcinolone injections. J Eur Acad Dermatol Venereol. Aug 2008;22(8):1028-9; author reply 1027-8. [Medline].
Hazey MA, Van Norman AJ, Armistead DL. Melkersson-Rosenthal Syndrome with migraine-like headaches treated with minocycline: a case report and review of the literature. W V Med J. Jan-Feb 2009;105(1):15-7. [Medline].
Ishiguro E, Hatamochi A, Hamasaki Y, Ishikawa S, Yamazaki S. Successful treatment of granulomatous cheilitis with roxithromycin. J Dermatol. Sep 2008;35(9):598-600. [Medline].
Print
